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Abstract
Idiopathic pulmonary fibrosis (IPF) is the most severe lung fibrotic form and very few pharmacological therapies are available at present. Key events in the onset of 
the disease are the activation of fibroblasts to myofibroblasts and the production and release of extracellular matrix (ECM) and molecular factors.
Primary murine lung fibroblasts were isolated and their activation induced by Bleomycin (BLM) treatment. Extracellular Vesicles (EV) were isolated and protein 
extracted. Released soluble proteins (Secretome) and EV-derived proteins were reduced, alkylated and trypsin digested. A nano-LC-MS/MS SWATHTM approach 
was used for the proteomics analyses.
Specific proteins with a putative role in the transition from physiological to fibrotic conditions, such as several matrix metalloproteinases (MMPs), osteopontin 
(OPN), chitinase-3-like protein1 (CHI3L1) and CD44 resulted differentially released from BLM-treated fibroblasts as compared with untreated lung fibroblasts. 
Our results provide further understanding of the pathophysiological features of lung fibrosis, and suggest specific target for pharmacological treatments. 
Abbreviations: BCA: Bicinchoninic Acid; BLM: Bleomycin; 
CHI3L1: Chitinase-3-Like Protein 1; DAB: Dark Brown Stain; 
DMEM-HG: Dulbecco’s Modified Eagle Medium High Glucose, 4500 
mg/L; ECM: Extracellular Matrix; EMT: Epithelial-Mesenchymal 
Transformation; FBS: Fetal Bovine Serum; FSP-1: Fibroblast-Specific 
Protein 1; GSN: Gelsolin; H&E: Haematoxylin and Eosin; H2O2: 
Hydrogen Peroxide; IIPs: Idiopathic Interstitial Pneumonias; IPF: 
Idiopathic Pulmonary Fibrosis; MANOVA: Multifactor Analysis Of 
Variance; MMP-1: Matrix Metalloproteinases-1; MMP-2: Matrix 
Metalloproteinases-2; MMP-3: Matrix Metalloproteinases-3; MMP-7: 
Matrix Metalloproteinases-7; MMP-9: Matrix Metalloproteinases-9; 
MMPs: Matrix Metalloproteinases; OPN: Osteopontin; PBS: Phosphate-
Buffered Saline; PDGF: Platelet-Derived Growth Factor; PRDX2: 
Peroxiredoxin 2; PRDX6: Peroxiredoxin 6; RNS: Reactive Nitrogen 
Species; ROS: Reactive Oxygen Species; S100A4: S100 Calcium-
Binding Protein A4; Tagln-2: Transgelin-2; TGF-β1: Transforming 
Growth Factor-β1; TNF-α: Tumor Necrosis Factor-α; Vim: Vimentin; 
α -sma: α-Smooth Muscle Actin.
Introduction
Fibrotic lung diseases represent a broad spectrum of pathologies 
characterized by different degrees of inflammation and fibrosis. In 
this group of disorders, the highest degree of fibrosis is expressed in 
idiopathic pulmonary fibrosis (IPF), whose pathogenesis is still unclear, 
thus its prognosis is highly unfavorable [1]. Specific therapeutic 
treatments are still missing, anti-fibrotic therapy with Pirfenidone 
or the tyrosine kinase inhibitor Nintendanib has been demonstrated 
only to reduce disease progression [2]. During pathology onset, 
repetitive damage events lead epithelial cells to apoptosis, fibroblasts 
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form “foci” and ECM components accumulate. Fibroblasts activate to 
myofibroblasts and express several cytokines and growth factors, such 
as PDGF, TGF-β1 and TNF-α, which stimulate cell migration and 
proliferation and extracellular matrix accumulation. Myofibroblasts 
are the major determinants of connective tissue remodeling in fibrotic 
disorders being also responsible for excessive ECM deposition, alveolar 
epithelial cell apoptosis and progressive destruction of lung parenchyma. 
All these processes end up to the progressive functional impairment of 
the lungs and, ultimately, to respiratory failure. Bleomycin (BLM) is the 
most widely used drug to induce pulmonary fibrosis in animals, being 
able to reproduce at least the main histologic characteristics observed 
in patients with IPF [3-5]. Presently, despite a better comprehension 
of fibrotic lung diseases lung transplantation remains the only real 
therapeutical opportunity for advanced IPF patients [6-8]. In this 
setting, we evaluated the modulation of protein synthesis and release in 
the BLM-induced phenotype switch from fibroblasts to myofibroblasts. 
In brief, secretome and proteins of microvesicles released by BLM-
treated lung fibroblasts were analyzed to obtain a general overview of 
the proteins released from activated cells in order to better understand 
the pathophysiological features of lung fibrosis.
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of each sample were processed, reducted with 5 mM DTT at 80°C for 
30 min, then cooled to room temperature and alkylated for 30 min at 
37°C with addition of iodoacetamide up to 10 mM final concentration. 
Digestion was performed by adding 0.50 µg of trypsin sequencing 
grade (Roche) at 37°C overnight and peptide mixtures were acidified 
with 10-20 µl of 1% formic acid.
Nano-LC-MS/MS SWATHTM analysis
Peptides were chromatographically separated using a nano-HPLC 
system (Eksigent, ABSciex). A first load step pre-concentrated the 
sample in a pre-column cartridge (PepMap-100 C18 5 µm 100 A, 0.1 x 
20 mm, Thermo Scientific, USA) and then peptides were separated in a 
C18 PepMap-100 column (3 µm, 75 µm x 250 mm, Thermo Scientific, 
USA) at a flow rate of 300 nL min-1. Runs were performed with eluent 
A (Ultrapure water, 0.1% FA) under 70 min linear gradient from 5 to 
40% of eluent B (ACN/0.1% FA) followed by 10 min of a purge step and 
20 min re-equilibration step. Peptides eluted from chromatography 
were directly processed using TripleTOFTM 5600 mass spectrometer 
(ABSciex, USA) equipped with a DuoSprayTM ion source (ABSciex, 
USA). Data were acquired using the new SWATHTM method for shotgun 
data independent MRM quantification. For library, MS/MS data were 
processed with ProteinPilotTM Software (ABSciex, USA) using the 
ParagonTM and Pro GroupTM Algorithms and Uniprot 2015 database 
for Mus musculus. The false discovery rate (FDR) analysis was set to a 
confidence level of 95%. The label free statistical comparative analysis 
was performed using PeakViewTM Software (ABSciex, USA) with MS/
MS(ALL) with SWATH™ Acquisition MicroApp 2.0 and MarkerViewTM 
(ABSciex, USA). Retention time alignment was obtained using 
selected peptides (top confidence and top level transitions) from top 
score protein of each analysis. Processing settings were: 7 peptides per 
protein, 7 transitions per peptide, 80% and 88% peptide confidence 
(according to Paragon algorithm result) respectively for secretome and 
microvesicles/exosomes and 5% FDR; XIC options: extraction window 
10 min, width 50 ppm and 0.1 Da. Normalization was done using a 
global normalization of profiles (total protein content). Principal 
Component Analysis (PCA) was performed in order to evidence 
groupings among the data set. Groups were compared with t-test using 
fold change (FC) > 2 and p-value < 0.05.
Western blot analysis
Protein extracts (20 µg) were run on a 10% SDS-PAGE and 
transferred onto a nitrocellulose membrane (Amersham) using Trans-
Blot SD Semi-Dry transfer cell (Biorad). The following antibodies were 
used: anti-osteopontin (anti-OPN, 1:500) (Meridian LifeScience); anti-
CD44 (1:300) (Abcam); anti-chitinase 3-like 1 (anti-CHI3L1; 1:300) 
(Biorbyt).
BLM in vivo administration
Wild-type C57BL/6 female and male mice were exposed to BLM 
(Sigma-Aldrich, Milan, Italy) by intratracheal instillation. Mice were 
anesthetized with ketamine/xylazine (Virbac, srl) (ketamine 80 mg/
kg intraperitoneal, xylazine 10 mg/kg intraperitoneal) and underwent 
intratracheal instillation of a single sub-lethal dose of 3 U/kg of BLM 
dissolved in 0.1 ml saline (0.9% NaCl). A control group underwent 
surgery for an intratracheal instillation of physiological saline solution. 
Mice were monitored for 28 days and then sacrificed.
Histological and immunohistochemical analyses
Mouse lungs were fixed by immersion in 5% buffered formalin for 
7-10 days. Following standard histology processing, 10-20 sections, 5 
Methods
Lung fibroblast isolation and culture
Lungs of healthy mice (8-10 weeks old) were explanted and tissue cut 
into small pieces (2-4 mm2). Wild-type C57BL/6 female and male mice 
(8-10 weeks old) were purchased from Harlan Laboratories. National 
guidelines for the care and the use of research animals, notified by the 
Italian ministry of health in accordance with Italian law (D.L. 116/92, 
implementation of EEC directive 609/86) were followed. The study 
was conducted in collaboration with the Fondazione Toscana Gabriele 
Monasterio and the Center of Experimental Biomedicine, CNR, in Pisa.
Tissue fragments were digested using 1 mg/ml Clostridial 
collagenase (Sigma-Aldrich, Milan, Italy) in phosphate-buffered saline 
(PBS) incubating at 37°C for 1 hour. After the enzymatic digestion, 
tissue fragments were centrifuged at 300 x g for 10 minutes at room 
temperature, resuspended in cell growth medium (Dulbecco’s Modified 
Eagle Medium High Glucose, 4500 mg/L (DMEM-HG), supplemented 
with 10% FBS, 2 mM L-glutamine and 1X penicillin-streptomycin 
solution) and cultured under standard conditions at 37°C for at least 24 
hours. The experiments were conducted with cells at the third passage.
MTT cell proliferation assay
For MTT Cell Proliferation Assay, lung fibroblasts were plated in 
96-well dishes (2000 cells/well). Three replicates for each experimental 
point were prepared. Cells were treated for 24, 48, 72 hours with the 
following concentrations of BLM: 0.5 μg/ml; 1.5 μg/ml; 2.5 μg/ml; 
3.5 μg/ml. 20 μl of MTT Reagent (CellTiter 96® Assay, Promega) were 
added for each well and cells were incubated up to 4 hours to 37°C, until 
purple precipitate was visible. At the end, the absorbance at 490 nm was 
recorded.
Secretome collection
Approximately 106 cells were seeded into 100 mm diameter culture 
dishes and cultured until cell density reached 90% confluence. For 
secretome analysis 3 dishes/experimental point (BLM-treated cells and 
control cells) containing 7 mL of culture FBS free-medium without 
phenol red were prepared. Conditioned medium was collected and 
centrifuged at 300 x g to eliminate cell debris. Salts were removed and 
protein concentrated by using Amicon Ultra-3 (Millipore) following the 
manufacturer’s recommendations. 
Extracellular vesicles (EV) isolation
For EV isolation, 20 dishes/experimental point (BLM-treated cells 
and control cells), each containing 7 mL of culture medium, were 
prepared and cells were cultured with 100 000 x g ultracentrifuged FBS 
to avoid bovine vesicle contaminations. Vesicles were isolated through 
differential centrifugations using the protocol described by Comelli et 
al. (2014) with minor changes [9]. Briefly, medium was centrifuged at 
2000 x g for 30 minutes to discard apoptotic blebs and at 110 000 x g for 
1 h at 4°C to obtain microvesicles and exosomes (EV). The pellet was 
washed with PBS centrifuging for 2 hours at 110 000 x g at 4°C and the 
resulted pellet stored at -80°C until analysis. In order to extract protein 
for MS analyses, vesicle pellets were lysed through 5 frozen-thaw cycles: 
30s in liquid nitrogen and then thawed at 50°C for 2 min; finally the 
samples were sonicated for 5 min.
Sample preparation for MS analysis
For secretome and EV samples, protein concentration was 
determined by bicinchoninic acid (BCA assay, Thermo Fisher). 40 µg 
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μm thick, were cut from paraffin embedded samples by rotary microtome 
(Microm HM 300, Bio-optica) and stained with Masson trichrome (Bio-
optica) for collagen. For immunohistochemistry, sections were placed 
on positively charged slides, deparaffinized, rehydrated and washed in 
distilled water. After incubation in H2O2 at room temperature, antigen 
retrieval was accomplished (citrate buffer pH= 6 in microwave for 
10 min at 500 W). The following primary antibodies were used: anti- 
α-smooth muscle actin (anti- α -SMA, 1:100) (Santa Cruz); anti-S100 
calcium-binding protein A4 (anti-S100A4, 1:500) (Novus biologics); 
anti- vimentin (anti- VIM, 1:50) (Santa Cruz); anti-osteopontin (anti-
OPN, 1:400) (Meridian Life Science); anti-chitinase 3-like 1 (anti-
CHI3L1; 1:300) (Biorbyt). Omission of the primary antibody served 
as a negative control. Antibody binding to cells and/or to extracellular 
components is visible as brown or dark brown stain (DAB), negative 
cells are blue stained (haematoxylin counterstain). All sections were 
examined under light microscopy (Olympus BX43) and digitized by a 
video system (Olympus D20 camera) interfaced to Olympus Cell Sens 
Dimension software for image acquisition.
Results 
Fibroblasts were isolated from lungs of healthy mice, cultured and 
treated with BLM, in order to induce and study the phenotypic changes 
that are likely connected with the fibrotic process.
To identify a dose of BLM able to determine phenotypic changes 
without inducing cell death, MTT assay was used and the drug was 
added to the cell culture in a specific range of concentration (from 0 
µg/ml to 3.5 µg/ml) for up to 72 hours. Cell viability decreased very 
slowly and never reached values below 70%. It started to decrease with 
1.5 µg/ml BLM and no differences were observed after 48 hours of 
treatment for all doses used. For these reasons, 1.5 µg/ml was chosen 
for successive experiments. 
In order to demonstrate the switch of lung fibroblasts to an activated 
phenotype, also referred to as myofibroblasts, when treated with BLM, 
immunohistological analyses were performed and the expressions of 
αSMA, S100A4 and vimentin (VIM) were examined. The expression 
of α-SMA (notoriously neo-expressed by myofibroblasts), and S100A4, 
which is a marker of pulmonary fibrosis increased in BLM-treated cells, 
while VIM (recognized marker for fibroblasts) was more expressed 
in untreated cells (Figure 1). These observations strengthened the 
hypothesis that primary cultures of lung fibroblasts treated with BLM 
can represent an in vitro model of lung fibrosis. 
For secretome analysis, fibroblasts were cultured until cell confluence 
reached 90% and incubated in serum-free medium supplemented or 
not with BLM for 48 hours. Mass spectrometry analysis allowed the 
identification of 263 proteins (Table S1). In Figure 2, the subcellular 
localization of these proteins is reported according to UniProt consortium 
(http://www.uniprot.org). In this specific setting, it is worth of note that 
44% of proteins are exosome, matrix and extracellular space proteins.   
Among the 263 identified proteins, 17 resulted differentially 
expressed in BLM-treated fibroblasts compared to untreated cells. 
These proteins, their p-values and fold changes are reported in 
Table S2. Table 1 shows the differentially expressed proteins that, 
according to literature, may be associated to the fibrotic process. 
To validate proteomics results, western blots were performed using 
anti-OPN antibody. OPN was found to be up-regulated in secretome 
of BLM-treated lung-fibroblasts as compared to the secretome of 
untreated cells (CTRL), confirming mass spectrometry based data.
The major drawback of secretome assessment is represented by the 
necessity to culture the cells in serum-free medium, a state of starvation 
and thus stress, due to the presence in serum of albumin and other 
abundant proteins that mask less abundant secreted proteins. In order 
to assess secreted proteins in more optimal physiological conditions, 
we isolated and studied extracellular vesicles (EV), i.e microvesicles 
and exosomes from BLM-treated lung fibroblasts cultured in standard 
conditions, in the presence of serum. 
This protocol allowed the identification of up to 464 proteins (Table 
S3). Identified proteins were grouped according to their subcellular 
localization (Figure 3). Forty-four proteins resulted differentially 
expressed and were analyzed according to their functions and activity, 
playing particular attention to their potential involvement in pulmonary 
Figure 1. Lung fibroblast immunocytochemistry: α-SMA and S110A4 in BLM untreated 
(left) and treated (right) fibroblasts (Scale bar=20µm)
Figure 2. Subcellular location of identified secretome proteins. Protein classification was 
made according to UniProt consortium http://www.uniprot.org. Western blot was carried 
out to validate secretome analyses for OPN expression in BLM-treated and control (CTRL) 
fibroblasts
Groups
DOWN regulated 
proteins 
BLM vs CONTROL
UP regulated proteins
BLM vs CONTROL
Chaperones Heat shock protein HSP 
90-alpha
Actin-binding proteins and 
cytoskeleton Cadherin-2
Extracellular matrix, MMPs 
and related factors Lysyl oxidase homolog 2
MMP-2
14-3-3 protein
MMP-3
Osteopontin
Inflammation and oxidative 
stress
Legumain
Chitinase-3-like protein 1
TGF-β Calreticulin
Table 1. Differentially secreted proteins
Proteins are grouped according to their putative involvement in lung fibrosis (p-value<0.05; 
Fold Change (FC) >2 for up-regulated and 1/FC >2 for down-regulated proteins)
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fibrosis. The complete list is stated in Table S4. In Table 2 were reported 
the differentially expressed proteins that can be associated to fibrosis 
according to the literature.
Western blot with anti-CD44 antibody was performed to validate 
the proteomics results; data shown in Figure 3 confirm a down-
regulation of this protein in BLM-treated cells. 
In order to investigate the possible transferability of the in vitro 
results to the in vivo animal model, mice were exposed to BLM (3 U/
kg) by intratracheal instillation, while a control group was treated with 
PBS. Animals were sacrificed after 28 days and lungs processed for 
histological analyses. In BLM-treated lungs, inflammatory infiltrates 
were evidenced and a marked production and accumulation of collagen 
fibers were detected in Mallory’s trichrome stain. Onset and progression 
of fibrosis was confirmed by immunohistochemical images showing an 
increase of positivity to both anti-α-SMA and anti-S100A4 in BLM-
treated tissue compared with untreated one (Figure 4). 
Immunohistochemistry analyses were also performed with 
antibodies specific for two differentially secreted proteins, osteopontin 
(anti-OPN) and chitinase-3-like protein 1 (anti-CHI3L1) (Figure 
5) both proteins were strongly expressed in treated fibrotic lungs, 
confirming and validating the proteomics results.
Discussion
Hallmarks of fibrosis progression and worsening are represented by 
hyper-proliferation of type II alveolar epithelial cells and recruitment 
and proliferation of fibroblasts, leading to an increase of fibroblastic 
foci. Activated fibroblasts are largely responsible for the production and 
deposition of interstitial collagen and other ECM components [10,11]. 
Specifically, when tissues are injured, locally residing connective 
fibroblasts acquire contractile activity by forming contractile stress 
fibers, neo-expressing α-SMA, while VIM expression decreases. In fact 
α-SMA expressing myofibroblasts not only promote contraction but 
also synthetize high levels of both extracellular matrix components and 
matrix degrading proteases playing a fundamental role in remodeling 
injured tissue [12-17]. A novel marker of pulmonary fibrosis is the 
fibroblast-specific protein 1 (FSP1) also identified as S100A4. Normal 
murine lung parenchyma expresses very low levels of S100A4, but 
its levels rapidly increase during BLM-induced pulmonary fibrosis. 
S100A4 expression is reported to correlate with collagen deposition 
and lung parenchyma architectural changes in the murine model of 
lung fibrosis. As evidenced in Figure 1 lung fibroblasts treated with 
BLM acquired the morphological and immunohistochemical features 
that characterize fibrosis. The main focus of this study is represented 
by the modulation of protein synthesis and release in the BLM-
Groups DOWN regulated proteins BLM vs CONTROL
UP regulated proteins
BLM vs CONTROL
Actin-binding 
proteins and 
cytoskeleton
Gelsolin
Septin-2
Filamin-C
Keratin, type II cytoskeletal 1
Extracellular matrix 
and related factors
Procollagen C-endopeptidase  
 enhancer 1
Protein-tyrosine kinase 2-beta
Oxidative stress and 
redox regulation
Flavin reductase
Peroxiredoxin-2
Peroxiredoxin-6
TGF-β
Chloride intracellular channel 
protein 4
Pigment epithelium-derived 
factor
Galectin-1
Coagulation factor V
CD44
Transgelin-2
DNA repair Nucleophosmin
Inflammation
Carboxypeptidase N catalytic 
chain
Cdc42
Carboxypeptidase B2
Calcium-binding 
proteins
Calmodulin
Calponin
Table 2. Differentially expressed proteins in released microvesicles
Proteins are grouped according to their putative involvement in lung fibrosis (p-value<0.05; 
Fold Change (FC) >2 for up-regulated and 1/FC >2 for down-regulated proteins)
Figure 3. Subcellular localization of total identified vesicle enclosed proteins. Protein 
classification was made according to UniProt consortium, http://www.uniprot.org. Western 
blot was carried out to validate proteomics data for CD44 expression in BLM-treated and 
control (CTRL) fibroblasts
Figure 4. Histological and immunohistochemical tissue characterization of BLM-induced 
lung fibrosis. Lung sections from mice treated with 3 U/Kg of bleomycin were compared 
with sections from physiological saline solution-treated mice. Representative micrographs 
of lung tissue stained with Mallory’s trichrome (Mallory) show focal areas of interstitial 
fibrosis in treated lungs (Scale bar=1 mm). Representative images for α-SMA and S100A4 
show positive areas of fibrosis in BLM-treated lungs. (Scale bar=500 µm)
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induced phenotype switch from fibroblasts to myofibroblasts. As 
a matter of fact, the activation and proliferation of lung fibroblasts 
precede accumulation of ECM components in the damaged alveolus 
and it is a key step in the transformation from a potentially reversible 
disorder to a progressive and irreversible one. Indeed, the amount of 
fibroblast/myofibroblasts foci is considered a main prognostic factor in 
pulmonary fibrosis disease [11]. In order to gain better insight in the 
fibrotic process, we analyzed the proteins released by BLM-activated 
fibroblasts. Secreted proteins play important roles in the regulation 
of many physiological processes via paracrine/autocrine mechanisms 
and they gained interest as potential biomarkers and therapeutic 
targets of diseases [18,19]. Moreover, the identification of proteins 
released in the extracellular space by fibrotic cells may be of great 
interest for the comprehension of lung fibrosis, being characterized by 
increased collagen deposition, accumulation of extracellular matrix 
components, cell proliferation/trans-differentiation and alteration of 
normal lung structure. 263 secreted proteins were identified, 44% are 
exosome, matrix and extracellular space proteins and among them 17 
resulted differentially expressed in BLM-treated fibroblasts compared 
to untreated cells. Several up-regulated proteins are factors related to 
ECM; it is worth of note that ECM plays a critical role in the repair 
process, orchestrating the transitions of cell phenotype and function 
[7,20].
Among the up-regulated proteins, osteopontin (OPN) is 
particularly interesting since recent studies reported that after BLM 
instillation, OPN -/- mice showed reduced lung fibrosis with decreased 
active transforming growth factor-beta 1 (TGF-β1) and reduced type 
I and type III collagen expression [21-23]. OPN also influences ECM 
remodeling by the alteration of collagen matrix and the induction of 
several matrix metalloproteinases (MMPs), such as MMP-1, MMP-
2 and MMP-9 [24]. It has long been accepted that MMPs play an 
important role in the pathogenesis of pulmonary fibrosis; as a matter of 
fact, we identified two up-regulated MMPs in BLM-treated fibroblasts: 
MMP-2 and MMP-3. MMP-1, MMP-2, MMP-7, and MMP-9 have 
been found highly expressed in pulmonary fibrosis and, in particular, 
in fibroblasts foci [25]. MMPs, including MMP-3, have the ability to 
regulate tissue repair altering the activity of non-matrix proteins, 
such as cytokines and membrane receptors, leading to the activation 
of pathways responsible of epithelial-mesenchymal transformation 
(EMT) [26]. As a consequence, MMP-3 could play a role in the origin 
of myofibroblasts [11]. Many factors and proteins interact with MMPs 
modulating their function and, among the others, the 14-3-3 proteins, 
a class of highly conserved molecular chaperones, represent important 
MMP-1 regulators. To close this interesting circle, it is of note that 
we also reported up-regulation of chitinase 3-like 1 (CHI3L1), that is 
involved in the inhibition of degradation of type I collagen by MMP-1 
[27-29].
Secreted vesicles represent a growing field of interest from a 
diagnostic point of view, aiming at identifying disease biomarkers in 
biological fluids (such as blood, urine, saliva) [9,30-32]. In the present 
study, the isolation of released vesicles allowed the identification of up 
to 464 proteins.
Forty-four proteins resulted differentially expressed and among 
them both peroxiredoxin 6 (Prdx6) and peroxiredoxin 2 (Prdx2) resulted 
down-regulated in BLM-treated fibroblasts suggesting a role for the redox 
system in fibrotic process. Peroxiredoxins are antioxidant enzymes and 
interestingly, Prdx2 was down-regulated in fibroblasts foci of idiopathic 
pulmonary fibrosis when compared to healthy control lungs [33]. 
Prdx6 is expressed at high levels in the lung where it has been 
recognized as a novel antioxidant enzyme that may play a critical role 
against oxidative damage [34]. Wang and colleagues demonstrated 
that transgenic mice overexpressing Prdx6 showed an increased 
resistance to lung injury in hyperoxia, leading to a major degradation 
of hydrogen peroxide (H2O2) and conferring protection against 
several forms of oxidative stress. As a consequence, the decreased 
enzyme expression should potentiate lung injury [35-38].  
Interestingly, several differentially expressed proteins are related to the 
TGF-β pathway since TGF-β is a potent fibrotic factor, an important 
activator of phenotype trans-differentiation from fibroblasts to 
myofibroblasts and its activity can be associated with the deposition 
and remodeling of ECM by stimulating cells to increase matrix protein 
synthesis, decrease the production of matrix-degrading proteases 
and modulate integrin expression [39]. CD44 is one of the proteins 
potentially involved in TGF-β pathway modulation, interacting with 
cytoskeletal components and other ligands, such as OPN, collagen and 
MMPs, influencing the adhesion and motility of fibroblasts, thereby 
supporting their potential role in tissue remodeling and fibrosis [40-
42]. Several studies suggested that the expression of CD44 play a major 
role in the resolution of inflammation and transition to reparative 
fibrosis in response to tissue injury. 
The phenotypic change towards an activated state is necessarily 
related to remodeling of actin cytoskeleton; in fact, several actin-
binding proteins were found differentially regulated in our samples. 
Among them, we found gelsolin (GSN) and transgelin-2 (Tagln-2) 
down-regulated in released vesicles from treated fibroblasts. This result 
is in line with the already published data in various types of cancer, 
rheumatoid arthritis and pulmonary fibrosis [43-45].
The different forms of pulmonary fibrosis in humans, in particular 
IPF, are burdened by high morbidity and mortality. Although 
pathogenic pathways and mediators of lung fibrosis have been in depth 
examined in the last few years, the molecular pathways involved are not 
fully understood so far. In animals treated with BLM, lung histology 
shows features similar to those present in humans with IPF. To provide 
a deeper insight in lung fibrotic pathogenetic mechanisms, proteomic 
analyses were undertaken on BLM-treated lung fibroblasts. Lung 
fibrosis is characterized by ECM synthesis and remodeling, therefore 
we focused on the study of secretome and microvesicle enclosed 
proteins. Several MMPs and ECM proteins resulted up-regulated in 
secretome of treated fibroblasts, as well as OPN, which plays a role 
Figure 5. Representative photomicrographs of immunostained lung sections. Lung 
sections from mice treated with 3 U/Kg of bleomycin were compared with sections from 
physiological saline solution-treated mice. Representative images for OPN and CHI3L1 
antibodies show positive areas of fibrosis in BLM-treated lungs. (Scale bar=500 µm)
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in both inflammation and tissue repair. The relevance of OPN in 
phenotype modulation of fibroblasts is confirmed by vesicle analyses 
that evidenced the differential expression of CD44, which interacts 
with OPN and MMPs and influences the inflammatory response. An 
increased expression of OPN and CHI3L1 in the fibrotic lung tissue 
in an animal model of BLM-induced fibrosis validated our proteomics 
results suggesting the possibility to translate in vitro data to in vivo 
settings. 
In conclusion, in an experimental model of BLM-induced lung 
fibrosis, several key proteins have been identified. The paucity of current 
clinical treatment represents a strong incentive to further research in 
order to assess whether these factors may be considered as potential 
targets for novel therapeutic approaches. 
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